Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Sandoz Buys Maker Of Dermatology Drugs
by Michael McCoy
May 7, 2012
| A version of this story appeared in
Volume 90, Issue 19
Novartis’ Sandoz unit will acquire Fougera Pharmaceuticals, a specialty dermatology generics company, for $1.5 billion in cash. Fougera is the former dermatology division of Nycomed, the rest of which was acquired last year by Takeda Pharmaceutical. Based in Melville, N.Y., Fougera had 2011 sales of $429 million. Sandoz says the purchase will make it the world’s number one generic dermatology medicines company with annual sales of about $620 million, primarily in the U.S.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X